Ductal carcinoma is the most common type of breast cancer. It begins in the cells that line the milk ducts. There are two main forms: non-invasive ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC). Staging ranges from stage 0 (DCIS) to stage IV (metastatic disease). Treatment is determined by the type, stage, and tumor characteristics, and may include surgery, radiation, hormone therapy, chemotherapy, or targeted drugs.
What Is Ductal Carcinoma?
Ductal carcinoma starts in the milk ducts, the tubes that carry milk from the lobules to the nipple. Normally, the cells lining those ducts grow and divide in an orderly way. In ductal carcinoma, something goes wrong and the cells begin to multiply out of control.
The key difference between the two main types comes down to whether those abnormal cells have broken through the wall of the duct. If the cells are still contained within the duct, it is called ductal carcinoma in situ (DCIS). If they have spread through the duct wall into the surrounding breast tissue, it is called invasive ductal carcinoma (IDC). Only invasive cancer has the potential to spread to lymph nodes and other parts of the body.
What Are the Types of Ductal Carcinoma?
There are two primary types, plus some less common subtypes that pathologists identify under the microscope.
Ductal Carcinoma In Situ (DCIS) is the non-invasive form. The abnormal cells are still inside the duct and have not invaded nearby tissue. DCIS is often found on a mammogram as tiny clusters of calcium deposits called microcalcifications. It is considered stage 0 breast cancer. Without treatment, some DCIS can progress to invasive cancer, but the risk is not the same for every case.
Invasive Ductal Carcinoma (IDC) is the most common type of breast cancer, accounting for about 80% of all invasive breast cancers. It starts in the duct but breaks through the wall and grows into the fatty tissue of the breast. From there, it can enter the lymphatics or bloodstream and spread to other organs.
Pathologists also identify special types of IDC based on how the cells look, such as tubular, medullary, mucinous, and papillary. These subtypes are less common and often have a better prognosis than the more usual “no special type” IDC. However, treatment decisions still mostly depend on stage and receptor status—estrogen receptor (ER), progesterone receptor (PR), and HER2—rather than the special type alone.
What Are the Stages of Ductal Carcinoma?
Staging describes how far the cancer has grown and spread. It helps guide treatment and gives a general idea of outlook. Doctors use the TNM system: Tumor size, lymph Node involvement, and Metastasis. From that they assign a stage from 0 to IV.
Stage 0 is DCIS only. No invasion.
Stage I is invasive but small. The tumor is 2 centimeters or smaller and has not spread to lymph nodes (IA), or there are tiny deposits in one node (IB).
Stage II covers larger tumors (2–5 cm) without node spread (IIA), or tumors up to 5 cm with spread to one to three axillary nodes (IIB), or tumors larger than 5 cm without node spread (IIB).
Stage III indicates more extensive local or regional spread. This includes tumors larger than 5 cm with node involvement (IIIA), spread to four or more nodes (IIIB), or involvement of chest wall or skin (IIIC). Inflammatory breast cancer is at least stage IIIB.
Stage IV means the cancer has metastasized to distant organs such as bone, liver, lung, or brain. This is also called metastatic breast cancer.
Staging also uses tumor grade (how abnormal the cells look) and receptor status. But the stage number itself is the strongest overall predictor of prognosis.
How Is Ductal Carcinoma Treated?
Treatment is not one-size-fits-all. It depends on whether the cancer is DCIS or IDC, the stage, hormone receptor and HER2 status, the patient’s age and overall health, and personal preferences.
For DCIS, the goal is to prevent progression to invasive cancer. Options include breast-conserving surgery (lumpectomy) followed by radiation, or mastectomy. For hormone receptor-positive DCIS, doctors often recommend taking tamoxifen or an aromatase inhibitor for five years to lower the risk of recurrence. Chemotherapy is not used for DCIS because it has no blood supply to carry the drugs to the abnormal cells inside the duct.
For IDC, treatment is more comprehensive. Surgery is almost always part of the plan—either lumpectomy plus radiation or mastectomy. Sentinel lymph node biopsy is done to check for spread. After surgery, many patients receive radiation, especially after lumpectomy. Systemic therapy is given based on the tumor’s biology:
- Hormone therapy (tamoxifen or an aromatase inhibitor) for ER-positive or PR-positive tumors. Typically taken for 5–10 years.
- Chemotherapy for triple-negative or HER2-positive tumors, or for higher-risk hormone-positive tumors. Given before surgery (neoadjuvant) or after.
- Targeted therapy (e.g., trastuzumab, pertuzumab) for HER2-positive cancers. Often combined with chemotherapy.
- CDK4/6 inhibitors for advanced hormone-positive cancers.
For stage IV disease, the focus is on controlling growth and maintaining quality of life. Local treatments like surgery are rarely used unless needed for a painful tumor. Systemic therapy is the mainstay, and new drugs continue to extend survival.
What Is the Prognosis for Ductal Carcinoma?
Prognosis depends mostly on stage at diagnosis. For DCIS, the outlook is excellent. Nearly all women with DCIS are alive five years after diagnosis. For early-stage IDC (stage I or II), the five-year survival rate is also very high—above 90 percent in most studies. For stage III, the five-year survival drops to around 70–80 percent. For stage IV, the five-year survival rate is about 30 percent, but this has been improving with new targeted therapies.
Other factors matter too. Hormone receptor-positive tumors grow more slowly and respond to hormone therapy. HER2-positive tumors are aggressive but respond to targeted drugs. Triple-negative breast cancer (no receptors) is more challenging to treat and has a higher recurrence risk in the first few years.
Overall, ductal carcinoma is highly treatable when caught early. Regular mammograms increase the chance of finding it at an early, curable stage.
Frequently Asked Questions
Is ductal carcinoma the same as breast cancer?
No. Ductal carcinoma is the most common type of breast cancer, but breast cancer also includes lobular carcinoma and other rare types.
Can DCIS become invasive?
Yes, some DCIS can progress to invasive ductal carcinoma if left untreated. The risk varies by the grade and size of the DCIS.
Does ductal carcinoma always require chemotherapy?
No. DCIS never requires chemotherapy. For IDC, chemotherapy is used only if the tumor is higher risk, such as triple-negative, HER2-positive, or large hormone-positive tumors with involved lymph nodes.
What is the survival rate for ductal carcinoma?
For DCIS and early-stage IDC, five-year survival exceeds 90 percent. For stage IV, five-year survival is lower, around 30 percent, but has improved with modern treatments.
